Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
08:15am, Tuesday, 31'st Aug 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
10:33am, Monday, 23'rd Aug 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--South San Francisco-based Veracyte was named a Bay Area Top Workplace for the eighth consecutive year.
Cathie Wood Whittles Down 2 Positions in July
12:51pm, Thursday, 12'th Aug 2021
Catherine Wood (Trades, Portfolio) disclosed earlier this week her firm, ARK Investment Management, reduced two of its positions in July.
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2021 Results - Earnings Call Transcript
10:33pm, Thursday, 29'th Jul 2021
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2021 Results - Earnings Call Transcript
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
08:31pm, Thursday, 29'th Jul 2021
Veracyte (VCYT) delivered earnings and revenue surprises of 48.00% and 15.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?
06:55am, Thursday, 29'th Jul 2021
Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position.
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
04:05pm, Thursday, 08'th Jul 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021.
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
08:45am, Thursday, 01'st Jul 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte has appointed Dr. Bill Bulman and Dr. Kelly Marcom as the company's medical directors of Lung Cancer and Breast Cancer, respectively.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced that new data demonstrating the prognostic utility of the Decipher® Prostate genomic classifier were published in JAMA Oncology.
Moving Average Crossover Alert: Veracyte (VCYT)
08:16am, Wednesday, 09'th Jun 2021
Veracyte (VCYT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Veracyte: Tumultuous Times
09:06am, Sunday, 06'th Jun 2021
Veracyte has seen a tumultuous 2021 so far. Shares have displayed great volatility and in fact, have seen a big pullback in recent times.
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
09:24am, Friday, 04'th Jun 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte received final Medicare coverage policies for Decipher Bladder, a molecular subtyping test for individuals with bladder cancer
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
04:27pm, Wednesday, 02'nd Jun 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Upcoming Investor Conferences
Veracyte to Present at Upcoming Investor Conferences
03:00pm, Wednesday, 02'nd Jun 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Upcoming Investor Conferences
Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition
12:22pm, Tuesday, 01'st Jun 2021
Veracyte Inc (NASDAQ: VCYT) has agreed to acquire HalioDx in a €260 million transaction to accelerate growth and strengthen its position in cancer diagnostics. The deal value consists of approxim
